* Somalogic Inc SLGC.OQ SLGC.O is expected to report
results on November 14.
* The New York City-based company is expected to report
revenue
of $20.075 million, according to the mean estimate from 4
analysts, based on Refinitiv data.
* Refinitiv's mean analyst estimate for Somalogic Inc is
for a
loss of 20 cents per share.
* The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Somalogic
Inc is
$8, above its last closing price of $2.97.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Jun. 30 2022 -0.20 -0.18 -0.13 Beat 26.4
Mar. 31 2022 -0.16 -0.16 -0.02 Beat 87.3
Dec. 31 2021 -0.11 -0.13 -0.13 Met -2
This summary was machine generated November 11 at 15:32 GMT.
All figures in US dollars unless otherwise stated